Prothena Corporation Public Limited Company (PRTA) Q2 FY2025 Largest Change: Net Loss Decreased 81.4%

Executive Summary

Prothena Corporation PLC reported its second quarter of fiscal year 2025 with significant improvements in its net loss figures, which decreased by approximately 81.4% compared to the same period last year. The company’s revenue declined slightly, but the reduction in net loss indicates enhanced operational efficiency and cost management. The company’s cash position decreased by 21.2% from December 31, 2024, reflecting ongoing investments and restructuring activities. Overall, the financials suggest a company in transition, focusing on pipeline development and strategic restructuring to improve long-term profitability.

Management Discussion and Analysis (MD&A)

During Q2 FY2025, Prothena continued to advance its pipeline of investigational therapeutics, with a focus on neurodegenerative and amyloid diseases. The company initiated a restructuring plan in June 2025, aimed at reducing operational costs and reallocating resources toward high-priority programs. The restructuring charges totaled approximately $32.6 million, primarily related to workforce reduction and contract terminations. Despite a 23.4% decrease in cash and cash equivalents to $371.4 million, management remains confident in the company’s liquidity for at least the next 12 months, supported by existing cash reserves and ongoing collaborations.

Income Statement Analysis

Revenue

Revenue for Q2 FY2025 was $4.42 million, a 96.7% decrease from $132.0 million in the same period last year. The decline is primarily due to reduced collaboration and license revenues as certain milestone payments were not achieved during the quarter. Sequentially, revenue decreased by 38.4% from the previous quarter, reflecting the winding down of some licensing activities.

Gross Profit and Operating Income

Gross profit data is not explicitly provided, but operating expenses totaled $89.04 million, including significant restructuring costs. Operating loss narrowed to $84.62 million from $58.38 million in the prior year, mainly due to lower R&D expenses and restructuring charges. The operating loss increased QoQ due to higher restructuring costs and lower revenue.

Net Income / Loss

Net loss for Q2 FY2025 was $125.8 million, a substantial improvement of 81.4% from a net loss of $66.9 million in the same period last year. The loss reduction is primarily driven by lower interest expenses and a decrease in income tax benefit, offsetting the decline in revenue. Earnings per share (EPS) was a loss of $2.34 per basic and diluted share, compared to earnings of $1.24 last year.

Balance Sheet Analysis

As of June 30, 2025, total assets decreased by 27.0% to $399.07 million from $547.11 million at year-end 2024. Cash and cash equivalents declined by 21.2% to $371.4 million. Total current assets decreased by 20.6%, mainly due to lower cash and receivables. Total liabilities increased slightly to $74.74 million, with current liabilities rising to $67.81 million, primarily due to restructuring liabilities. Shareholders’ equity decreased by 33.3% to $324.3 million, reflecting accumulated deficits and share repurchases or issuance adjustments.

Cash Flow Analysis

Net cash used in operating activities was approximately $99.7 million for the quarter, primarily due to net loss adjustments and working capital changes. Investing activities involved capital expenditures of $0.13 million. Financing activities resulted in a net outflow of $0.12 million, mainly from share repurchases or issuance activities. The company’s cash burn rate remains high, but liquidity is supported by existing cash reserves and ongoing collaboration payments.

Ratios & DuPont Analysis

Prothena’s net profit margin improved significantly due to reduced net losses, now at -2847.6%. Return on assets (ROA) remains negative at -31.6%, reflecting ongoing R&D investments. Return on equity (ROE) is also negative at -38.8%. Asset turnover is low at 0.011, indicating limited revenue generation relative to assets. The equity multiplier is 1.23, suggesting moderate leverage. The DuPont analysis underscores the company’s focus on cost control and pipeline advancement amid ongoing losses.

Risk Factors

Key risks include regulatory delays, clinical trial failures, and dependence on collaborations with Roche, BMS, and Novo Nordisk. Market competition in neurodegenerative therapeutics is intense, and the company’s financial position requires careful management of liquidity and capital raising. Macroeconomic factors and currency exchange rate fluctuations also pose risks, especially given the euro-denominated expenses and Irish operations. Operational risks from restructuring and workforce reductions could impact ongoing R&D productivity.

Notes & Additional Commentary

Unusual items this quarter include a restructuring charge of $32.6 million, primarily related to workforce reductions and contract terminations. The company’s pipeline progress remains cautious, with no new milestone payments recognized during the quarter. The decline in revenue reflects the winding down of some licensing activities, but strategic focus on core programs is expected to improve future prospects. The company’s net loss reduction is a positive sign, but profitability remains distant in the near term.

Investment Implications

Prothena’s current valuation is heavily influenced by pipeline potential and ongoing restructuring efforts. Short-term opportunities include potential milestone payments from collaborations and strategic licensing. Long-term risks involve clinical trial outcomes and regulatory approvals. The company’s liquidity position provides runway for continued R&D, but investors should remain cautious about execution risks and the need for additional capital raises. A balanced outlook suggests monitoring pipeline developments and cost management strategies for sustainable growth.